Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
Zenopa, you have done it again! By 'it' I mean you have supported my application to a great company where so far, I feel like I fit right in.
Natasha, 2013

Roche ends collaboration with Ligand

26 November 2010 00:00 in Pharmaceutical Company Product News


Roche has ended its agreement with Ligand Pharma after two years.

The two firms signed a collaboration and license agreement to develop new treatments for hepatitis C viral infections in 2008, but Roche is exercising its right to terminate the agreement.

Roche made a $6.5 million (4.1 million pounds) milestone payment to Ligand in April this year, following the initiation of the RG7348 Phase I clinical trial.

Under the terms of the agreement, Ligand will now receive a non-exclusive, worldwide, royalty-bearing license under specified Roche patents to develop and sell related compounds and products.

Roche will be unable to develop or commercialise related compounds for the next ten years.

Ligand received notice of the termination on Friday November 19th 2010. It is expected that the termination will be in effect 60 days after written notice was given.

Earlier this month, it was reported that Roche has embarked on a strategic partnership with Capital Bio, targeting molecular diagnostic applications and the development of research technologies.ADNFCR-8000103-ID-800257273-ADNFCR

Other news stories from 26/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd